Tryp Therapeutics (CSE: TRYP) (OTC: TRYPF) Files Provisional Patent for New Psychedelic Delivery Methods

Last week, Tryp Therapeutics issued a statement announcing the submission of a provisional patent to enhance how psychedelics are dispensed across various indications. Tryp Therapeutics is a pharmaceutical company engaged in the development of compounds with known activity and safety profiles for the treatment of rare ailments that currently have no approved treatments. The company has a psilocybin program called the PFN(TM) program that works on developing synthetic psilocybin as a new therapy for specific neuropsychiatric disorders.

The patent details new techniques for the development, dosing and delivery of psychedelics, which may help decrease the time a patient spends in a state of dissociation.

These techniques make up the fundamental elements of Tryp’s medical treatment program that is currently in development for a broad range of conditions. The patent is only the beginning of more filings to come, which will improve psychedelics efficacy.

The patent comprises of a technique that measures the response to psychedelic therapies, which further supports a better psychedelic experience. The application also includes techniques to manufacture active pharmaceutical ingredients, new formulations and techniques to improve the safety of therapies and decrease the risk of addiction and abuse.

Tryp Therapeutics has a drug candidate TRP-8802, which has been developed to treat fibromyalgia, an acute pain syndrome that affects approximately 5 million individuals in the Unites States. In addition,  Tryp Therapeutics is engaged in preparations to commence a phase 2 clinical study that will look into different eating disorders. Furthermore, the company is also developing a treatment for soft tissue sarcoma, which are diverse and rare tumors that make up nearly 7% of cancers in children and 1% in adults. The frequency of the disease in the U.S. and its rarity makes the company’s drug candidate eligible to apply for Orphan Drug Status.

Tryp Therapeutics president Jim Gilligan, who also happens to be the company’s chief science officer, stated that the company was seizing this opportunity, which would help transform its intellectual property position in the field of psychedelics through the formulation, delivery and dosing of active ingredients. Gilligan added that he was impressed by the determination of the company’s team of advisors and researchers, noting that the innovations were considerably broadening the availability of alternative treatment options for patients whose medical needs are yet to be met by showing how effective and safe the company’s psychedelic drug programs are.

It should be noted that Tryp Therapeutics isn’t the only player holding patents in the psychedelics field. Canada-based Cybin Corp. (NEO: CYBN) (OTCQB: CLXPF) also has a total of eight provisional patents for psychedelic drug formulations and delivery technologies, and many other firms have made filings.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Archives

Select A Month

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050